

Regd. Office :
'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015. India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 2368
www.zyduscadila.com
CIN:L24230GJ1995PLC025878

BSE Limited 1 st Floor, P.J. Towers Dalal Street <u>Mumbai – 400 001</u>	National Stock Exchange of India Limited Exchange Plaza, 5 th Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East) <u>Mumbai – 400 051</u>
Kind Attn.: Mr. Sanjay Golecha / Mr. Gopalkrishnan	Kind Attn.: Famroze Pochara Asst. Vice President
Date: August 22, 2017	
Re.: Press Release	

Dear Sir / Madam,


We enclose herewith a copy of press release dated August 22, 2017 titled "Zydus receives final approval from the USFDA for Pindolol Tablets USP"

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking You,

Yours faithfully,
For, **CADILA HEALTHCARE LIMITED**



UPEN H. SHAH
COMPANY SECRETARY

Encl.: As above

Zydus receives final approval from the USFDA for Pindolol Tablets USP

Ahmedabad, 22 August 2017

Zydus Cadila has received the final approval from the USFDA to market Pindolol Tablets USP, 5 mg and 10 mg. Pindolol belongs to a class of medication called beta-blockers and is used to treat hypertension. The drug will be manufactured at the group's formulations manufacturing facility at the Pharma SEZ, Ahmedabad. The sales of Pindolol tablets is estimated at \$83.59 million. *Source: IMS Health, IMS National Sales Perspective Audit, MAT June 2017, extracted August 2017.*

The group now has more than 140 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
